229 related articles for article (PubMed ID: 9465096)
1. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
Nagy A; Schally AV; Halmos G; Armatis P; Cai RZ; Csernus V; Kovács M; Koppán M; Szepesházi K; Kahán Z
Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1794-9. PubMed ID: 9465096
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.
Nagy A; Schally AV; Armatis P; Szepeshazi K; Halmos G; Kovacs M; Zarandi M; Groot K; Miyazaki M; Jungwirth A; Horvath J
Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7269-73. PubMed ID: 8692981
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
Nagy A; Armatis P; Cai RZ; Szepeshazi K; Halmos G; Schally AV
Proc Natl Acad Sci U S A; 1997 Jan; 94(2):652-6. PubMed ID: 9012839
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of receptors for somatostatin in various tumors using different analogs.
Srkalovic G; Cai RZ; Schally AV
J Clin Endocrinol Metab; 1990 Mar; 70(3):661-9. PubMed ID: 1968467
[TBL] [Abstract][Full Text] [Related]
5. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.
Koppan M; Nagy A; Schally AV; Arencibia JM; Plonowski A; Halmos G
Cancer Res; 1998 Sep; 58(18):4132-7. PubMed ID: 9751625
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238.
Kahán Z; Nagy A; Schally AV; Hebert F; Sun B; Groot K; Halmos G
Int J Cancer; 1999 Aug; 82(4):592-8. PubMed ID: 10404076
[TBL] [Abstract][Full Text] [Related]
7. Superactive octapeptide somatostatin analogs containing tryptophan at position 1.
Cai RZ; Karashima T; Guoth J; Szoke B; Olsen D; Schally AV
Proc Natl Acad Sci U S A; 1987 Apr; 84(8):2502-6. PubMed ID: 2882520
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
Plonowski A; Schally AV; Nagy A; Sun B; Szepeshazi K
Cancer Res; 1999 Apr; 59(8):1947-53. PubMed ID: 10213505
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin.
Cai RZ; Szoke B; Lu R; Fu D; Redding TW; Schally AV
Proc Natl Acad Sci U S A; 1986 Mar; 83(6):1896-900. PubMed ID: 2869490
[TBL] [Abstract][Full Text] [Related]
10. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.
Schally AV; Nagy A
Eur J Endocrinol; 1999 Jul; 141(1):1-14. PubMed ID: 10407215
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, Cytotoxicity and Antioxidant Activity of New Analogs of RC-121 Synthetic Derivatives of Somatostatin.
Naydenova E; Wesselinova D; Staykova S; Goshev I; Vezenkov L
Anticancer Agents Med Chem; 2018; 18(10):1417-1424. PubMed ID: 29667555
[TBL] [Abstract][Full Text] [Related]
12. Comparison of somatostatin and its highly potent hexa- and octapeptide analogs on exocrine and endocrine pancreatic secretion.
Konturek SJ; Bilski J; Jaworek J; Tasler J; Schally AV
Proc Soc Exp Biol Med; 1988 Feb; 187(2):241-9. PubMed ID: 2448802
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Schally AV; Redding TW
Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238.
Plonowski A; Schally AV; Koppan M; Nagy A; Arencibia JM; Csernus B; Halmos G
Cancer; 2001 Sep; 92(5):1168-76. PubMed ID: 11571730
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor-targeted anti-cancer therapy.
Sun LC; Coy DH
Curr Drug Deliv; 2011 Jan; 8(1):2-10. PubMed ID: 21034425
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase.
Liebow C; Reilly C; Serrano M; Schally AV
Proc Natl Acad Sci U S A; 1989 Mar; 86(6):2003-7. PubMed ID: 2564678
[TBL] [Abstract][Full Text] [Related]
17. Effect of somatostatin analogs on gastric acid secretion in dogs and rats.
Schally AV; Colaluca J; Paulson D; Carter WH; Neitzschman HR; Lafaye H; Cai RZ
Int J Pept Protein Res; 1990 Sep; 36(3):267-74. PubMed ID: 1980670
[TBL] [Abstract][Full Text] [Related]
18. Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238.
Keller G; Engel JB; Schally AV; Nagy A; Hammann B; Halmos G
Int J Cancer; 2005 May; 114(5):831-5. PubMed ID: 15609311
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.
Engel JB; Schally AV; Halmos G; Baker B; Nagy A; Keller G
Cancer; 2005 Sep; 104(6):1312-21. PubMed ID: 16047355
[TBL] [Abstract][Full Text] [Related]
20. Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.
Erchegyi J; Waser B; Schaer JC; Cescato R; Brazeau JF; Rivier J; Reubi JC
J Med Chem; 2003 Dec; 46(26):5597-605. PubMed ID: 14667214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
